title: [Changes in endometrial vascularisation due to hormone therapy in menopause].
abstract: Hysteroscopic and histopathologic endometrial study by commune and immunohistochemical techniques on 2 groups of menopausal women on HRT-sequential (24 months) and continuous combined (12 months) compared to pretherapy or a control untreated group showed the changes of endometrial superficial microvascular net-work, with new blood vessels and ecquimosis/subepithelial haemorrhages. Endometrial neoangiogenesis varied according to progestogens/progesterone: type (less on dydrogesterone, more important on cyproterone acetate, medroxyprogesterone acetate, norethisterone), dose (large doses of medroxyprogesterone acetate induce greater changes in sequential HRT, and small doses induce less changes), time (minimum when progestogen is cyclic at 3 months). The vascular changes are more accentuate in the first year of HRT. The correlation between the number of new vessels and type of endometrial pathology showed that the neoangiogenesis is greater in secretory and atrophic endometrium.
authors.affiliation: Universitatea de Medicină şi Farmacie Carol Davila Bucureşti, Departamentul Universitar de Obstetrică-Ginecologie Dr. I. Cantacuzino.
authors.forename: Manuela
authors.initials: M
authors.lastname: Russu
authors.forename: Dana
authors.initials: D
authors.lastname: Terzea
authors.forename: D
authors.initials: D
authors.lastname: Hudiţă
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D004717:Endometrium / Q000098:blood supply* / Q000187:drug effects*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects* / Q000379:methods; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D006801:Humans; D015907:Hysteroscopy; D007150:Immunohistochemistry; D008593:Menopause; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000139:chemically induced*; D011374:Progesterone / Q000008:administration & dosage / Q000009:adverse effects*; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies
chemical_list: D004967:Estrogens; D011372:Progestins; D011374:Progesterone